ImmuPharma PLC (AIM:IMM, FRA:25I) has signed up Kymos Group as its bioanalytical partner for diabetes drug Kapiglucagon. That completes the outsourced team needed to file for human trials in the US. ValiRx PLC (AIM:VAL, FRA:EAJF) is set to get a second European patent for its cancer-killing peptide from subsidiary Cytolytix. It's targeting triple negative breast cancer and is in talks with a major pharma company. Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) has drilled some strong copper and silver hits at its Mushima North project in Zambia. Lab results are due in the coming weeks, with a resource estimate targeted by the end of the year. Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL, VFEX:CMCL) has kept its 2026 gold production target after output jumped 18% quarter on quarter. Revenue, profit and earnings per share were all up sharply too. Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF, FRA:3ZX1, AIM:SEI) will talk to shareholders after a third voted against its new equity pay plan. All resolutions still passed, and the CEO says big catalysts are coming over the next year. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.

Thermo Fisher Scientific (NYSE:TMO) has been selected by ImmuPharma as the key drug product and contract development manufacturer for its Kapiglucagon diabetes treatment program. The partnership covers development and manufacturing support for Kapiglucagon, an experimental therapy aimed at addressing diabetes. This agreement adds a new project to Thermo Fisher Scientific’s pharmaceutical services portfolio, focused on complex drug development work. For investors tracking Thermo Fisher...

Seeing Machines (AIM:SEE) has won a new driver monitoring contract with a European carmaker worth around $5 million in lifetime revenue, just as new EU safety rules make the technology mandatory on new vehicles. Production starts in 2028, with the system built into a rear-view mirror for easy deployment across multiple platforms. Frontier IP (LSE:FIPP) says portfolio company Cambridge Raman Imaging has secured a €400,000 European grant to scale up its AI-powered pharmaceutical quality control technology. The company has also appointed a China-based distributor with over 100 customers globally. ImmuPharma (AIM:IMM) has appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon. That completes the main manufacturing partnerships alongside Swiss group Bachem, which is handling the active ingredient. MP Evans (AIM:MPE) grew crude palm oil production 11% to 192,300 tonnes in the first half, supported by higher harvests across its Indonesian estates. Pricing also held firm at around $873 per tonne. Ariana Resources (AIM:AAU) says its Tavşan gold mine in Türkiye has completed its ramp-up and is now processing ore at the required rate of at least 4,000 tonnes a day. Gold recovery is tracking at around 70%. 88 Energy (AIM:88E) has moved its Augusta-1 Alaska well closer to a first-quarter 2027 spud after securing a rig and camp. Prospective resources at South Prudhoe have also been upgraded by 35%. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy

Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF) has delivered strong early results from its biggest ever drilling campaign at the Pitfield titanium project in Western Australia. Multiple thick, near-surface intercepts above 7% TiO₂ have confirmed a high-grade core that management calls "a defining moment for Pitfield." ImmuPharma PLC (AIM:IMM, FRA:25I) is advancing its Kapiglucagon diabetes drug towards US human trials, engaging specialist consultancy tranScrip to prepare for an FDA pre-IND meeting. The drug targets next-generation artificial pancreas systems in a market forecast to hit $13.6 billion by 2035. Light Science Technologies Holdings PLC (AIM:LST, FRA:9FD) has landed its first contract as a supplier of Injectaclad fire-resistant cladding material, just weeks after acquiring the product's owner. The £410,000 order covers a five-storey residential building in East Yorkshire, with work starting in early May. Kodal Minerals PLC (AIM:KOD) says revenue from its first three shipments at the Bougouni lithium project in Mali has topped $89 million. The third cargo of around 20,000 tonnes is currently in transit to China, with final payment expected on arrival in July. Active Energy Group PLC (AIM:AEG, OTCID:AEUSF) is accelerating revenue by redeploying digital infrastructure onto its Ghummud site, shifting pre-sold customers onto live capacity ahead of the UAE site coming online. At full capacity, Ghummud is expected to generate $400,000 per MVA per year, with that level expected within six weeks. Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF, FRA:RR1) is exploring a US stock exchange listing as it looks to strengthen its ties with North American investors and western rare earths supply chains. The move follows strong US investor participation in its recent fundraise, including backing from Traxys, a partner in the US government's $12 billion critical materials stockpiling programme. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.

Rome Resources Plc (AIM:RMR, FRA:33R) says drilling at its Kalayi prospect in the Democratic Republic of Congo has delivered its strongest tin intercepts so far. Early readings point to high-grade mineralisation, with a resource update expected once assays land. Great Southern Copper PLC (LSE:GSCU, FRA:E9E) has identified new gold-copper targets at its Viuda prospect in Chile. A large concealed anomaly could drive the next phase of drilling in the second quarter. European Green Transition PLC (AIM:EGT) has built a £126 million pipeline in wind repowering projects. The company says demand is rising fast following UK planning changes and stronger energy security focus. Active Energy Group PLC (AIM:AEG, OTCID:AEUSF) has completed the acquisition of the Ghummud grid connection asset in Abu Dhabi for £2 million. The deal adds immediate power capacity and could generate around $1.8 million in annual revenue. ImmuPharma PLC (AIM:IMM, FRA:25I) is pushing ahead with partnering talks for its P140 autoimmune platform. In a letter to shareholders, chairman Tim McCarthy said a £6.5 million fundraise extends the cash runway to 2028 and supports further development. Astrid Intelligence PLC (AQSE:ASTR) has increased its holding in the Zeus AI subnet by nearly 24%. The investment focuses on weather prediction tools for energy markets using decentralised data. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.

ImmuPharma (AIM:IMM, FRA:25I) says it's on track to deliver a licensing deal for its lead asset P140 this year. The company has also fast-tracked Kapiglucagon, a next-gen diabetes treatment, backed by funding from Lanstead Capital. Ilika (AIM:IKA, OTCQX:ILIKF, FRA:I8A) has had its Goliath solid-state batteries tested under battlefield conditions — including live-fire testing. The results demonstrated the inherent safety advantages of Ilika’s solid-state battery technology compared to traditional lithium-ion alternatives Coinsilium (AQSE:COIN, OTCQB:CINGF, FRA:5CT) is betting on prediction markets as its big focus for 2026. The sector is already worth over $65 billion, and the company is investing in Prediction Labs, which sits in the data infrastructure layer of the market. IP Group (LSE:IPO) posted 13% growth in NAV per share for 2025. Highlights include a near 50x return from the Hinge Health IPO and a £130 million valuation tied to Pfizer's obesity drug pipeline. Team Internet Group (AIM:TIG, OTCQX:TIGXF, FRA:4CN) says its transition year is done, with 80% of EBITDA now coming from its more stable domains and comparison platforms. The company is also reviewing a potential sale of the DIS division, with any proceeds targeted at repaying debt and rewarding shareholders. Follow us and subscribe on YouTune, our social channels, and on proactiveinvestors.co.uk.

ImmuPharma PLC (AIM:IMM, FRA:25I) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company's latest developments, including progress on its lead asset P140, a newly accelerated program for Kapiglucagon, and recent fundraising activity. McCarthy emphasised that P140 remains the company’s primary focus, with ongoing licensing discussions described as highly active. He stated, “We are delivering a deal this year. We're confident of doing that,” highlighting continued engagement with multiple potential partners, including new parties that have approached the company since late 2025. Alongside this, ImmuPharma has advanced Kapiglucagon into an accelerated development program following interest and funding support from existing shareholders. The asset, targeting Type 1 diabetes (T1D), is designed to address limitations in current glucose delivery systems. McCarthy explained that Kapiglucagon offers improved solubility and stability, making it suitable for next-generation dual hormone pumps. The company has secured funding led by Lanstead Capital Investors to support a two-year development plan, with the goal of progressing Kapiglucagon toward potential licensing discussions. McCarthy noted that early engagement with industry players has already generated strong interest. Despite the expansion of its pipeline, McCarthy reiterated that the company’s strategy remains centred on P140, stating that “our total focus has not been diverted one iota in pushing forward those license discussions.” For more insights into ImmuPharma’s strategy and upcoming milestones, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates. #ImmuPharma #TimMcCarthy #P140 #Kapiglucagon #BiotechNews #PharmaNews #DrugDevelopment #DiabetesResearch #Type1Diabetes #BiotechInvesting #HealthcareInnovation #ClinicalDevelopment #LicensingDeals #SmallCapStocks #AIMStocks

Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF) says new drilling confirms a high-grade zone at its Pitfield titanium project in Australia. A bigger drill campaign is underway, with an updated resource expected in the third quarter. Atlantic Lithium Ltd (AIM:ALL, ASX:A11, OTCID:ALLIF) has secured around $16 million to push its Ewoyaa project in Ghana forward. The funding brings in local pension funds and supports key milestones toward production. ImmuPharma PLC (AIM:IMM, FRA:25I) is raising up to £7.5 million to develop a new Type 1 diabetes treatment. It also says a licensing deal for its lead drug remains on track this year. IP Group PLC (LSE:IPO) returned to growth last year with NAV per share up 13% after a tough 2024. The boost came from Pfizer’s Metsera deal and ongoing portfolio exits. Light Science Technologies Holdings PLC (AIM:LST, FRA:9FD) raised £600,000 in a retail offer that was heavily oversubscribed. Total fundraising now stands at £6.6 million. ATOME PLC (AIM:ATOM) has earned an “Excellent” rating for its green finance framework. That supports its low-carbon Villeta fertiliser project in Paraguay backed by a $420 million debt deal. Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.